Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC3 | O15379 | 16/20 | 0.66 |
| ▸ | HDAC1 | Q13547 | 16/20 | 0.66 |
| ▸ | HDAC2 | Q92769 | 13/20 | 0.66 |
| ▸ | HDAC10 | Q969S8 | 9/20 | 0.66 |
| ▸ | HDAC4 | P56524 | 9/20 | 0.66 |
| ▸ | HDAC6 | Q9UBN7 | 8/20 | 0.66 |
| ▸ | HDAC7 | Q8WUI4 | 7/20 | 0.66 |
| ▸ | HDAC11 | Q96DB2 | 7/20 | 0.66 |
| ▸ | HDAC8 | Q9BY41 | 7/20 | 0.66 |
| ▸ | HDAC9 | Q9UKV0 | 7/20 | 0.66 |
| ▸ | HDAC5 | Q9UQL6 | 7/20 | 0.66 |
| ▸ | NCOR2 | Q9Y618 | 5/20 | 0.66 |
| ▸ | MEN1 | O00255 | 1/20 | 0.53 |
| ▸ | RAB9A | P51151 | 1/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20545185 | 1.00 | HDAC3 (0.66) | HDAC3HDAC1HDAC2HDAC10HDAC4 | |
| SCHEMBL20545053 | 0.99 | HDAC3 (0.63) | HDAC3HDAC1HDAC2HDAC10HDAC4 | |
| SCHEMBL20544906 | 0.90 | HDAC3 (0.73) | HDAC3HDAC1HDAC2HDAC10HDAC4 | |
| SCHEMBL20545019 | 0.90 | HDAC3 (0.73) | HDAC3HDAC1HDAC2HDAC10HDAC4 | |
| SCHEMBL20590124 | 0.89 | HDAC3 (0.70) | HDAC3HDAC1HDAC2HDAC10HDAC4 | |
| SCHEMBL20545051 | 0.88 | MEN1 (0.70) | HDAC3HDAC1HDAC2HDAC10HDAC4 | |
| SCHEMBL20545061 | 0.87 | HDAC3 (0.61) | HDAC3HDAC1HDAC2HDAC10HDAC4 | |
| SCHEMBL20544899 | 0.86 | RAB9A (0.71) | HDAC3HDAC1HDAC2HDAC10HDAC4 | |
| SCHEMBL15668783 | 0.86 | HDAC3 (0.69) | HDAC3HDAC1HDAC2HDAC10HDAC4 | |
| Hydrochloric Acid SCHEMBL17045868 | 0.84 | HDAC3 (0.68) | HDAC3HDAC1HDAC2HDAC10HDAC4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12478594-B2 | Methods of treatment of kidney injury associated with infection or trauma | University of Pittsburgh—of the Commonwealth System of Higher Education (US) | 2025-11-25 | — | — | US | claimed |
| US-20200207691-A1 | Class of HDAC Inhibitors Expands the Renal Progenitor Cells Population and Improves the Rate of Recovery from Acute Kidney Injury | UNIVERSITY OF PITTSBURGH - OF T | 2020-07-02 | — | — | US | disclosed |
| US-20200207691-A1 | Class of HDAC Inhibitors Expands the Renal Progenitor Cells Population and Improves the Rate of Recovery from Acute Kidney Injury | UNIVERSITY OF PITTSBURGH - OF T | 2020-07-02 | — | — | US | disclosed |
| US-10626071-B2 | Class of HDAC inhibitors expands the renal progenitor cells population and improves the rate of recovery from acute kidney injury | University of Pittsburgh—of the Commonwealth System of Higher Education (US) | 2020-04-21 | — | — | US | disclosed |
| US-10626071-B2 | Class of HDAC inhibitors expands the renal progenitor cells population and improves the rate of recovery from acute kidney injury | University of Pittsburgh—of the Commonwealth System of Higher Education (US) | 2020-04-21 | — | — | US | disclosed |
| US-10160705-B2 | Class of HDAC inhibitors expands the renal progenitor cells population and improves the rate of recovery from acute kidney injury | University of Pittsburgh—of the Commonwealth System of Higher Education (US) | 2018-12-25 | — | — | US | disclosed |
| US-20180312455-A1 | Class of HDAC Inhibitors Expands the Renal Progenitor Cells Population and Improves the Rate of Recovery from Acute Kidney Injury | UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION | 2018-11-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10160705-B2 | Class of HDAC inhibitors expands the renal progenitor cells population and improves the rate of recovery from acute kidney injury | HDAC1, HDAC9, HDAC11 | HDAC3 9/4885HDAC1 1/4885HDAC2 6/4885 |
| US-10626071-B2 | Class of HDAC inhibitors expands the renal progenitor cells population and improves the rate of recovery from acute kidney injury | HDAC1, HDAC9, HDAC11 | HDAC3 9/4885HDAC1 1/4885HDAC2 6/4885 |
| US-20180312455-A1 | Class of HDAC Inhibitors Expands the Renal Progenitor Cells Population and Improves the Rate of Recovery from Acute Kidney Injury | HDAC1, HDAC9, HDAC11 | HDAC3 9/4885HDAC1 1/4885HDAC2 6/4885 |
| US-20200207691-A1 | Class of HDAC Inhibitors Expands the Renal Progenitor Cells Population and Improves the Rate of Recovery from Acute Kidney Injury | HDAC1, HDAC9, HDAC11 | HDAC3 9/4885HDAC1 1/4885HDAC2 6/4885 |
| US-12478594-B2 | Methods of treatment of kidney injury associated with infection or trauma | HDAC1, HDAC2, HDAC4 | HDAC3 7/4885HDAC1 1/4885HDAC2 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.